PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (HGH SUPPORT)
DRUG NAME: TESAMORELIN

  • FDA Safety Data Sheet can be found here.

  • Sinha DK. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 [PubMed Link]

  • Svensson J. Growth hormone secretagogues as therapeutic agents. Growth Horm IGF Res. 1999 [PubMed Link]

  • Clemmons DR. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 [PubMed Link]

  • Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013 [PubMed Link]

  • Stanley TL. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 [PubMed Link] 

  • Spooner LM. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012 [PubMed Link]

  • Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011 https://pubmed.ncbi.nlm.nih.gov/21668043/

  • Lake JE. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021 [PubMed Link]

  • Wang Y. Tesamorelin, a human growth hormone releasing factor analogue. Expert Opin Investig Drugs. 2009 [PubMed Link]

  • Rahman F. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2022 [PubMed Link]

  • González-Sales M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015 [PubMed Link]

  • Adrian S. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019 [PubMed Link]

  • Falutz J. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008 [PubMed Link]

  • Mateo MG. Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy. Expert Rev Endocrinol Metab. 2011 [PubMed Link]

  • Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011 [PubMed Link]

  • Sigalos JT. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017 [PubMed Link]

  • Ferro P. Structure-activity relationship for peptídic growth hormone secretagogues. Drug Test Anal. 2017 [PubMed Link]